| + |
B6;129-C3tm1Crr Man2a1tm1Jxm/J
|
|
|
mutant stock
|
JAX
|
17
|
C3tm1Crr
|
targeted mutation 1, Michael C Carroll
|
complement component 3
|
targeted mutation
|
| 17
|
Man2a1tm1Jxm
|
targeted mutation 1, Jamey Marth
|
mannosidase 2, alpha 1
|
targeted mutation
|
| + |
B6;129-Man2a1tm2Jxm/J
|
|
|
mutant stock
|
JAX
|
17
|
Man2a1tm2Jxm
|
targeted mutation 1, Jamey Marth
|
mannosidase 2, alpha 1
|
targeted mutation
|
| ? |
B6129S5-Man2a1Gt(OST432549)Lex
|
|
|
mutant strain
|
TAC
|
17
|
Man2a1
|
mannosidase 2, alpha 1
|
mannosidase 2, alpha 1
|
gene trap
|
| ? |
BayGenomics ES cell line GST047
|
|
|
unclassified
|
MMRRC
|
17
|
Man2a1Gt(GST047)Byg
|
gene trap GST047, BayGenomics
|
mannosidase 2, alpha 1
|
gene trap
|
| ? |
BayGenomics ES cell line KST059
|
|
|
unclassified
|
MMRRC
|
17
|
Man2a1Gt(KST059)Byg
|
gene trap KST059, BayGenomics
|
mannosidase 2, alpha 1
|
gene trap
|
| ? |
BayGenomics ES cell line RST069
|
|
|
unclassified
|
MMRRC
|
17
|
Man2a1Gt(RST069)Byg
|
gene trap RST069, BayGenomics
|
mannosidase 2, alpha 1
|
gene trap
|
| ? |
BayGenomics ES cell line RST596
|
|
|
unclassified
|
MMRRC
|
17
|
Man2a1Gt(RST596)Byg
|
gene trap RST596, BayGenomics
|
mannosidase 2, alpha 1
|
gene trap
|
| ? |
BayGenomics ES cell line TEA128
|
|
|
unclassified
|
MMRRC
|
17
|
Man2a1Gt(TEA128)Byg
|
gene trap TEA128, BayGenomics
|
mannosidase 2, alpha 1
|
gene trap
|
| ? |
Man2a1tm1e(KOMP)Wtsi
|
|
|
mutant strain
|
KOMP
|
17
|
Man2a1tm1a(KOMP)Wtsi
|
targeted mutation 1a, Wellcome Trust Sanger Institute
|
mannosidase 2, alpha 1
|
targeted mutation
|
| 17
|
Man2a1tm1e(KOMP)Wtsi
|
targeted mutation 1e, Wellcome Trust Sanger Institute
|
mannosidase 2, alpha 1
|
targeted mutation
|